Vivek Sharma

Employment

• University of Louisville
• University of Louisville

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (127)

• Acquired haemophilia A associated with prostate cancer managed with recombinant activated factor VII and emicizumab.
  BMJ Case Reports 2026 DOI: 10.1136/bcr-2026-274804
  +Save
• BXQ-350 in combination with FOLFOX7 and bevacizumab: Evaluation of effect on oxaliplatin-induced CIPN and neutropenia—A phase 1b/2a trial to assess the efficacy and safety of BXQ-350, a first-in-class sphingolipid metabolism modulator, in newly diagnosed…
  Journal of Clinical Oncology 2026 DOI: 10.1200/jco.2026.44.16_suppl.12080
  +Save
• Abstract CT162: Analysis of tumor and biomarker responses in the VIRAGE Trial, a randomized Phase IIb, open-label, study of nab-paclitaxel and gemcitabine with/without intravenous VCN-01 in patients with metastatic pancreatic cancer (mPDAC)
  Cancer Research 2026 DOI: 10.1158/1538-7445.am2026-ct162
  +Save
• Utility of Circulating Tumor DNA to Assess Tumor Response in Patients with Locally Advanced Rectal Cancer Undergoing Neoadjuvant Therapy
  Cancers 2026 DOI: 10.3390/cancers18040589
  +Save
• A phase 1b/2 study on the efficacy and safety of BXQ-350, a first-in-class sphingolipid metabolism modulator, in combination with mFOLFOX7 and bevacizumab in newly diagnosed metastatic colorectal carcinoma.
  Journal of Clinical Oncology 2026 DOI: 10.1200/jco.2026.44.2_suppl.tps273
  +Save
• BXQ-350 efficacy and safety evaluation in first line mCRC patients: A phase 1b/2 study of BXQ-350, a first-in-class sphingolipid metabolism modulator, in combination with mFOLFOX7 plus bevacizumab in newly diagnosed metastatic colorectal carcinoma.
  Journal of Clinical Oncology 2026 DOI: 10.1200/jco.2026.44.2_suppl.242
  +Save
• Bxq-350 in combination with FOLFOX7 and bevacizumab: Evaluation of effect on oxaliplatin-induced CIPN—A phase 1b/2 trial to assess the efficacy and safety of BXQ-350, a first-in-class sphingolipid metabolism modulator, in newly diagnosed metastatic color…
  Journal of Clinical Oncology 2026 DOI: 10.1200/jco.2026.44.2_suppl.105
  +Save
• A Case Report of Non‐Neutralizing Acquired Factor V Inhibitor Mimicking Deficiency: Diagnostic Challenges and Therapeutic Implications
  Case Reports in Hematology 2026 DOI: 10.1155/crh/4306324
  +Save
• 2216MO VIRAGE trial: Randomized phase IIb, open-label, study of nab-paclitaxel and gemcitabine with/without intravenous VCN-01 in patients with metastatic pancreatic cancer (mPDAC)
  Annals of Oncology 2025 DOI: 10.1016/j.annonc.2025.08.2833
  +Save
• Real-world Monitoring of ctDNA Reliably Predicts Cancer Recurrence and Treatment Efficacy in Patients with Resected Stages I-III Colon Cancer.
  Annals of Surgery 2025 DOI: 10.1097/sla.0000000000006887
  +Save